Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071891 | 1.00 | KDM4E (0.33) | KDM4EALDH1A1NLRP3POLBTSHR | |
| SCHEMBL6071947 | 0.88 | KDM4E (0.42) | KDM4EALDH1A1NLRP3POLBTSHR | |
| SCHEMBL6071869 | 0.85 | KDM4E (0.37) | KDM4EALDH1A1GLAKMT2A | |
| SCHEMBL6071864 | 0.85 | KDM4E (0.37) | KDM4EALDH1A1GLAKMT2A | |
| SCHEMBL6072247 | 0.85 | MAPT (0.40) | KDM4EMAPTKMT2AHTT | |
| SCHEMBL6072235 | 0.85 | MAPT (0.40) | KDM4EMAPTKMT2AHTT | |
| SCHEMBL6071868 | 0.84 | KDM4E (0.37) | KDM4EALDH1A1GLAKMT2A | |
| SCHEMBL6071874 | 0.84 | KDM4E (0.37) | KDM4EALDH1A1GLAKMT2A | |
| SCHEMBL6072332 | 0.83 | KDM4E (0.36) | KDM4EALDH1A1HSD17B10GLAKMT2A | |
| SCHEMBL6072741 | 0.83 | KDM4E (0.38) | KDM4EALDH1A1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | KDM4E 358/4885ALDH1A1 423/4885NLRP3 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.